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A B S T R A C T
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a disease in pregnancy characterized by maternal
alloantibodies directed against the human platelet antigen (HPA). These antibodies can cause intracranial he-
morrhage (ICH) or other major bleeding resulting in lifelong handicaps or death. Optimal fetal care can be
provided by timely identification of pregnancies at risk. However, this can only be done by routinely antenatal
screening. Whether nationwide screening is cost-effective is still being debated. HPA-1a alloantibodies are es-
timated to be found in 1 in 400 pregnancies resulting in severe burden and fetal ICH in 1 in 10.000 pregnancies.
Antenatal treatment is focused on the prevention of fetal ICH and consists of weekly maternal IVIg adminis-
tration. In high-risk FNAIT treatment should be initiated at 12–18 weeks gestational age using high dosage and
in standard-risk FNAIT at 20–28 weeks gestational age using a lower dosage. Postnatal prophylactic platelet
transfusions are often given in case of severe thrombocytopenia to prevent bleedings. The optimal threshold and
product for postnatal transfusion is not known and international consensus is lacking. In this review practical
guidelines for antenatal and postnatal management are offered to clinicians that face the challenge of reducing
the risk of bleeding in fetuses and infants affected by FNAIT.
1. Introduction
Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare
but severe disease in pregnancy. FNAIT develops in pregnancy due to
maternal alloimmunization and results in thrombocytopenia and a risk
of bleeding in the fetus and neonate. Clinical presentation may vary
from an asymptomatic thrombocytopenia as a finding by chance to skin
bleeding or severe organ bleeding [1]. The most severe complication
being intracranial hemorrhage (ICH), that can lead to perinatal death or
lifelong neurologic sequelae [2]. FNAIT is the most frequent cause of
thrombocytopenia in otherwise healthy born neonates with an in-
cidence of approximately 1 in 1500 pregnancies [3]. As FNAIT is a rare
condition and often not recognized by clinicians, this entails difficulties
to determine the burden of this disease on population level [4]. In
addition, strong evidence for the optimal antenatal and postnatal
treatment is lacking due to the limited number and size of randomized
trials or observational studies [5,6]. In this review we aim to summarize
the current knowledge about the epidemiology of FNAIT and provide an
overview on antenatal and postnatal management strategies based on
the most recent literature.
2. Pathogenesis
In FNAIT, maternal exposure to incompatible, paternally derived,
fetal HPA can lead to immunization and formation of alloantibodies.
During pregnancy, active transport of IgG takes place form the mother
to the unborn child over the placenta by binding to the neonatal Fc-
receptor (FcRn) [7,8]. Hence, IgG class HPA-alloantibodies bind to fetal
platelets, leading to phagocytosis of the fetal platelets causing throm-
bocytopenia and a risk of bleeding in these infants [9,10]. Thrombo-
cytopenia in FNAIT does not only result from the destruction of plate-
lets, but may also worsen due to the suppression of platelet production
by megakaryocytes. Suppression of megakaryocytopoesis has recently
been shown in in vitro experiments in the presence of HPA-1a alloan-
tibodies [11].
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2.1. Human platelet antigens
Maternal alloantibody formation is triggered by exposure to in-
compatible HPA. Nowadays 35 HPAs are known and described. HPAs
are epitopes present on five cell surface platelet glycoproteins (GP)
[12,13]. These glycoproteins play an important role in platelet function
for instance adhesion, aggregation and hemostatic plug formation [14].
Approximately 80 % of the FNAIT cases in the Caucasian population are
caused by alloantibodies directed the HPA-1a epitope. Therefore, we
will focus on anti-HPA-1a-mediated FNAIT in this review unless stated
otherwise. The HPA-1a is carried by the β3 integrin, which is part of the
fibrinogen receptor [15]. The β3 integrin is also expressed in complex
with the αV integrin as the vitronectin receptor, by endothelial cells,
the placenta syncytiotrophoblasts and by other tissue during develop-
ment of the human embryo [16–18]. This finding has led to interesting
ideas about early immunization and functional effects of alloantibodies
in FNAIT.
2.2. Immunization
Immunization in FNAIT can occur early in pregnancy and lead to
clinically relevant disease already in first affected pregnancies. The
relevance of these immunizations was questioned by Skogen et al. [19]
mentioning that the rate of immunization in primigravidae was 8–24 %.
However, in two case series describing intracranial hemorrhages (ICH)
due to FNAIT, ICH occurred in first pregnancies in 24–27 % of the cases,
underlining that immunization and clinically relevant disease can occur
already in early stages of first pregnancies [2,20]. Previous research
highlighted the contribution of several risk factors that play a role in
HPA immunization during pregnancy. For some HPA antigens, such as
HPA-1a, the exposure of the HPA-1a epitope on the placenta may play
an important a role [21]. Furthermore, if HPA-1a negative women carry
the MHC class II allele HLA-DRB3*01:01, this may promote the anti-
HPA-1a immune response, due to optimal HPA-1a peptide presentation
[22,23].
2.3. Functional effects of antibodies
Approximately 10–25 % of children with a severe thrombocyto-
penia caused by FNAIT develop an ICH [4]. However, the relationship
between ICH and thrombocytopenia is not linear and the majority of
FNAIT children do not develop an ICH. It may very well be that cranial
bleedings are not solely caused by thrombocytopenia. The observation
in a murine model with thrombocytopenic fetuses that were born
without ICH supports this idea [24]. The expression of the β3 chain on
both platelets and endothelial cells lead to the idea that bleedings in
FNAIT can occur by the binding of antibodies to endothelial cells. An-
imal studies and ex vivo studies with human cord blood derived en-
dothelial cells showed that HPA-antibodies directed against the β3-
chain reduced endothelial cell proliferation, angiogenesis and en-
dothelial integrity [25,26]. Santoso et al. [27] recently found a larger
proportion of vitronectin-receptor specific antibodies in maternal sera
of FNAIT cases with ICH, compared to the sera from pregnancies
without the occurrence of an ICH in the infant. The occurrence of ICH in
fetuses and neonates with FNAIT may result from the combination of
severe thrombocytopenia and endothelial damage, leading respectively
to insufficiency of the hemostatic system and vessel wall injury.
3. Epidemiology
Knowledge about the epidemiology of FNAIT is obtained from ret-
rospective data of cases sent to reference laboratories and prospective
screening studies. Studies with a retrospective study design are often
prone for bias. Not the least because FNAIT cases are often missed and
underdiagnosed in the absence of a nationwide screening programme
[28,29]. FNAIT as a cause of intrauterine fetal demise (IUFD) is often
not considered and the burden of FNAIT might be even larger when
miscarriages and IUFD are taken into account. Large prospective
screening studies that address the incidence of FNAIT have been per-
formed in several countries (Table 1). In general, studies with a pro-
spective study design are less prone for bias. However, interventions in
these studies might influence the outcome of the disease, which makes
it difficult to assess the natural course of the disease. In addition it
should be noted that two types of screening studies have been per-
formed; postnatal screening studies that screen for alloantibodies in
thrombocytopenic neonates [30–35] and antenatal screening studies
that assess neonatal outcome after screening for antibodies, mainly
performed in HPA-1a-negative women [36–46].
3.1. Incidence of HPA-alloantibodies
Incidence of HPA-alloantibodies varies due to genetic variation be-
tween populations [13]. In 2004 Davoren et al. [47], described the HPA
specificity of 1162 different FNAIT cases in a Caucasian population. Based
on this study, around 80 % of the FNAIT cases are caused by HPA-1a
alloantibodies. HPA-5b alloantibodies are responsible for ∼ 10 % of the
FNAIT cases. When cases with HPA-2, -3 and -15 alloantibodies are added
to this list approximately 95 % of the FNAIT cases are covered [47]. In the
Table 1
Prospective cohort studies assessing the incidence of FNAIT.
Author, year HPA-1a negative Antenatal anti-HPA-1a Platelet count
< 50 × 109/l
Mild bleeding Severe bleeding Intervention
Mueller-Eckhardt, 1985 [36] 26/1,211 (2.1) 2/26 (7.7) 0 0 0 None
Reznikoff-Etievant, 1988 [37] 27/860 (3.1) 0/27 (0) 0 0 0 None
Blanchette 1990 [38] 81/5,000 (1.6) 3/50 (6.0) 1 0 1 NTCS, PP
Doughty, 1995 [42] 74/3,473 (3.2) 1/71 (1.4) 0* 0* 0 FBS/IUPT, IVIg, PP
Durand-Zaleski, 1996 [40] 52/2,066 (2.5) 4/45 (8.9) 1 0 0 FBS, IVIg, CTS
Williamson, 1998 [41] 618/24,417 (2.5) 37/385 (9.6)** 8 7 1 PP
Davoren, 2003 [42] 54/4,090 (1.3) 2/34 (5.9) 1 1 0 FBS, IUPT, PP
Maslanka, 2003 [43] 144/8,013 (1.8) 12/122 (9.8) 3 1 0 IUPT, IVIg
Turner, 2005 [44] 546/26,506 (2.1) 25/318 (7.9) 5 3 0 PP
Kjeldsen-Kragh, 2007 [45] 2,111/100,448 (2.1) 144/1,990 (7.2) 48 NR 2 NTSC, PP
Debska, 2018 [46] 373/15,204 (2.5) 22/373 (5.9) 3 NR NR IUPT, IVIg
Numbers are n/N (%). CST, antenatal corticosteroids; FBS, fetal blood sampling; FNAIT, fetal and neonatal alloimmune thrombocytopenia; HPA, human platelet
antigen; IUPT, intrauterine platelet transfusion; IVIg, antenatal intravenous immunoglobulins; NR, not reported; NT, not tested; NTCS, near-term cesarean section;
PLT, platelet count; PP, postnatal platelets available for transfusion. Severe FNAIT is defined as neonatal platelet count at birth<50 × 109/L. Mild bleeding is
defined as only skin or mucosal bleeding. Severe bleeding is defined as internal organ hemorrhage or ICH.
* One HPA-1a negative women delivered two severely affected twin children, anti-HPA-1a antibodies detected after birth, not detected by prenatal screening.
** Two pregnancies ended in loss of the baby, one at 15 weeks, another as neonatal death from immaturity after CS at 25 weeks for severe pre-eclampsia.
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Asian population most FNAIT cases are caused by antibodies directed
against HPA-5b, followed by anti-HPA-4b; the HPA-4 antigens are present
on the β3-integrin like HPA-1 [48]. Since most studies are based on pa-
tient series that were collected retrospectively it is difficult to estimate
natural occurrence and pathogenicity of these alloantibodies. Based on
the available studies, antibodies against low frequent antigens are rare,
and their contribution to the morbidity of FNAIT in the Caucasian po-
pulation is negligible [49].
Kamphuis et al. [3] performed a systematic review on the incidence
of FNAIT in 2010. In total 176,084 antenatal screened pregnancies were
included. Based on these studies the authors estimated that 2.1 % of the
pregnant women are HPA-1a negative in the Caucasian population and
therefore at risk for FNAIT. The risk of antibody formation in HPA-1a
negative women during reproductive age was calculated to be 9.7 %
(294 of the 3028 cases). In 2018 Debska et al. [46] found that the risk of
antibody formation was 8.6 % in the study population of Polish
screening programme. In a recent Norwegian study, the risk of post-
partum immunization for an HLA-DRB3*01:01 positive women deli-
vering an HPA-1a positive child was calculated to 12.7 % [50].
3.2. Incidence of severe thrombocytopenia
Clinical symptoms in FNAIT vary from asymptomatic thrombocy-
topenia to severe (intracranial) hemorrhages. In literature, FNAIT
is often defined as neonates with alloantibodies and a platelet
count< 50×109/L with or without ICH. Differences in definitions on
severe FNAIT makes it difficult to compare different studies and assess
the natural history of FNAIT. Kamphuis et al. [4] assessed the incidence
of severe FNAIT in a review in 2014 and compared antenatal and
postnatal screening studies. The incidence of severe FNAIT, defined as
platelet count< 50 × 109/L, was estimated to be 0.04 % in both an-
tenatal and postnatal screening studies [4].
3.3. Incidence of intracranial hemorrhages (ICH)
The development of ICH is not directly associated with the severity
of thrombocytopenia, given that only a small proportion of severely
thrombocytopenic infants actually suffer from bleeding complications
[4]. In addition to this, severe bleedings have been described in cases
with moderate thrombocytopenia [51]. Shortage of platelets is there-
fore unlikely to be the only factor that causes ICH. Over the last years
more evidence emerged showing that the maternal alloantibodies can
also cause damage to the endothelium that might result in ICH [26,27].
It is not known at which moment in pregnancy the developing brain is
most vulnerable for damage induced by these kind of alloantibodies. It
may also be that these types of alloantibodies do not only lead to ICH
but also to other type of cerebral damage or small bleedings. These
lesions can remain subclinical directly after birth but lead to develop-
mental delay on the long term.
Two cohort studies by Tiller et al. [20] and Winkelhorst et al. [2]
described the localization and extensiveness of FNAIT-related ICH. In
these studies, 43 and 21 cases, respectively were described. Approxi-
mately 90 % of these cases were caused by HPA-1a alloantibodies. Tiller
et al. [20] described that the majority of the bleedings were in-
traparenchymal. This finding was confirmed by Winkelhorst et al. [2]
showing that 19 bleedings were intraparenchymal complicated by hy-
drocephalus in 11 cases. The survival rate of children with ICH due to
FNAIT varied from 65 % to 52 %. The risk on neurological sequelae in
survivors was high, ranging from 70 % to 53 %.
The incidence of ICH varies from 9.9 % – 25 % of the severe FNAIT
cases based on antenatal and postnatal screening studies, respectively
(Fig. 1) [4]. Antenatal screening studies may underestimate the in-
cidence of ICH as imaging was not performed routinely in all screening
studies. However, Refsum et al. [52] performed a retrospective cohort
study and assessed the presence of HPA alloantibodies in a cohort of
neonates born with an ICH. In this study, HPA alloantibodies were only
found in 3 of the 105 maternal serum samples. The authors acknowl-
edge that this study might be affected by bias, although the study im-
plicates that the true incidence on FNAIT-related ICH might be less than
previously thought.
The recurrence rate of ICH in FNAIT is difficult to assess since stu-
dies are retrospective and biased by different treatment interventions.
In addition, as severe cases might be more likely to be published, stu-
dies on this subject are also more prone for publication bias. In 2003
Radder et al. [53] performed a retrospective cohort study to assess the
recurrence risk of ICH after a pregnancy complicated by an ICH due to
FNAIT. The recurrence rate of an ICH due to FNAIT in subsequent
pregnancies was estimated on 79 %. Besides ICH, other life-threatening
organ bleedings, like pulmonary, ocular and gastrointestinal bleedings,
are described in FNAIT [54,55]. Since these bleedings are less well
known and probably underreported, it is impossible to estimate the
incidence of these bleedings [1].
4. Antenatal management
The majority of ICH in FNAIT develop during pregnancy [20]. These
Fig. 1. Epidemiology of anti-HPA-1a induced FNAIT.
HPA: Human platelet antigen, FNAIT: Fetal and neonatal alloimmune thrombocytopenia, ICH: intracranial haemorrhage, Severe thrombocytopenia is defined as a
platelet count below 50 × 109/L.
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hemorrhages have an important contribution to the burden of FNAIT.
To prevent these ICH, treatment during pregnancy must be initiated
early enough in pregnancy. Alloantibodies develop without clinical
symptoms during pregnancy. Details about diagnostics of these anti-
bodies are published by Porcelijn et al. [56] in this issue. The only way
to prevent severe complications in first pregnancies is by screening and
timely antenatal treatment. In the absence of routine screening, an-
tenatal treatment is mostly started in subsequent pregnancies after the
first affected child was born. When FNAIT is suspected, diagnostic tests
should confirm or rule out FNAIT, in this way clinical management can
be adapted adequately in the future. Clinicians are challenged to reduce
the risk of bleedings in FNAIT, this can be done by treatment during
pregnancy. In the past, the mainstay of treatment was based on invasive
intrauterine platelet transfusions, similar to blood transfusions in red
cell immunization. Nowadays, non-invasive approaches using maternal
IVIg administration have been shown to be equally or even more ef-
fective, and preferable due to a reduced risk of complications.
4.1. Risk stratification
If FNAIT is confirmed antenatally, pregnancies should be closely
monitored by a specialised obstetrician. Currently we use the clinical
outcome of a previous FNAIT pregnancies for risk stratification. Some
studies show that alloantibody levels could predict disease severity
[57]; an approach which has been used in Norway for two decades
[58]. However severe FNAIT cases have been described with low an-
tibody titres implicating that sensitivity is low [59]. It may be that
pregnancies with HPA-5b or HPA-15b antibodies could be considered as
low risk pregnancies and alloantibodies against HPA-1a and HPA-3a as
high risk, however, the risk for the individual pregnancy on an HPA-
alloantibody mediated bleeding in the infant can yet not be predicted.
Data set from large prospective studies comparing clinical outcome of
different HPA antibodies will be the first step to adjust clinical man-
agement for different HPA types. Despite efforts to find a reliable
prognostic marker until know, no single marker has been found to
predict disease severity accurately. Maternal HLA-DRB3*01:01 status is
suggested as a prognostic marker for immunization and formation of
potent HPA-1a antibodies during pregnancy. More research is needed to
confirm these findings.
4.2. Intrauterine transfusions
Fetal blood sampling (FBS) and intrauterine platelet transfusions
(IUPTs) were traditionally the only treatment options to reduce the risk
of ICH and severe thrombocytopenia. Intrauterine intravascular, ultra-
sound-guided red blood cell transfusions to treat fetal anemia were
introduced in the 1980s. Daffos and colleagues [60] were the first that
applied this technique on FNAIT. After their successful first intra-
uterine platelet transfusion others followed. However, there are im-
portant differences between intra-uterine red blood cell transfusions for
fetal anemia compared to platelet transfusions for fetal thrombocyto-
penia. Since the fetus is at risk for bleeding due to FNAIT, puncture of
the umbilical cord is a dangerous procedure. In addition, the half-life of
the transfused platelets is short, making it necessary to perform weekly
transfusions. The high risk of complications related to fetal blood
sampling or intra uterine transfusions was confirmed in a recent sys-
tematic review by Winkelhorst et al. [5]. In total, 26 studies were in-
cluded, of which 4 were randomized controlled trails, 5 prospective
studies and 17 retrospective studies. The most frequently reported
complication due to FBS or IUPT was an emergency cesarean section.
The authors describe that complications occurred in 11 % of the
pregnancies treated with invasive therapy (54 of 497 treated preg-
nancies in 24 studies). Complications resulted in fetal death or neonatal
loss in 26 % of cases. The overall mortality rate was 4 %, with more
than half of the mortality related to FBS/IUTP [5].
4.3. Maternal intravenous immunoglobulins (IVIg) administration
In the past, IVIg administration was successfully used in pregnancies
complicated by maternal idiopathic thrombocytopenic purpara (ITP).
Later, in 1988, Bussel and colleagues [61] were the first to report a
positive effect of antenatal maternal IVIg treatment in pregnancies with
FNAIT. IVIg are made from human IgG antibodies extracted from
pooled human donor blood. The exact therapeutic mechanism of ma-
ternal IVIg treatment is unknown. The various proposed mechanism
that could be responsible for the effect are discussed by Wabnitza H
et al. [62] in this issue. Evidence about optimal treatment options is
obtained mostly from cases series and was recently summarized in a
systematic review as part of an international guideline on FNAIT
[5,63].
In the absence of a reliable clinical or biochemical marker to predict
platelet count or clinical outcome on FNAIT, treatment is based on the
obstetric medical history. FNAIT pregnancies are usually classified as
‘high risk’ in case of a previous pregnancy with a severely affected child
with ICH or severe hemorrhage, while all other pregnancies with sibling
with FNAIT without ICH are considered as ‘standard risk’. First line
treatment in high risk pregnancies is weekly maternal IVIg adminis-
tration from 12 to 16 weeks of gestational age with a standard dosage
regime of 1 g/kg/week. In some centres, dosage is increased to 2 g/kg/
week around 20 weeks gestational age and/or corticosteroids are
added. Since side effects of IVIg treatment are dose-dependent and the
beneficial effect of increment in dosage is based on low evidence,
therapy is not intensified in high risk pregnancies in the Netherlands. In
a randomized trial to assess the optimal dosage in FNAIT the risk on
adverse outcomes was not different between low-dose (0.5 g/kg/wk) or
high dose (1.0 g/kg/wk) [64]. As this trial was stopped early due to
poor recruitment a definitive conclusion regarding dose could not be
drawn from this trial. Yet the standard dosage regimen in standard risk
pregnancies at our center has been lowered to 0.5 g/kg/wk. Treatment
in standard risk pregnancies is usually started from 20 to 28 weeks
gestational age, antenatal management strategies in the Netherlands
are summarized in Fig. 2.
IVIg administration is performed blindly, without FBS or IUPT, and
this makes it impossible for clinicians to monitor the therapeutic effect
of this treatment. Side effects can be classified in maternal and fetal side
effects. The most important maternal side effects are headache and flu-
like symptoms. One case of maternal pancytopenia was reported, in this
case full blood count was normalized spontaneously 6 weeks after
pregnancy [65,66]. Possible long-term effects on the development the
immune system of children are not well known. In one study, complete
blood count and leukocyte differentiation were assessed in 20 cord
blood samples, and in this study no abnormal maturation of the im-
mune system was seen in children with FNAIT who received antenatal
IVIg treatment or IUPT [67]. In the same cohort, a questionnaire study
was performed and showed no increase of pediatric infections in IVIg
treated cases. However, treatment regime in this cohort was hetero-
geneous and groups were small [68]. Since side effects of maternal IVIg
treatment during pregnancies on the development of the fetus were not
assessed adequately and no randomized placebo-controlled trial was
perfomed to show clinical efficacy, IVIg treatment for this indication is
still ‘off label’. This, despite the fact that IVIg treatment is re-
commended in virtually all guidelines. Additional studies on maternal
and neonatal effects of IVIg are required, including the effects on long-
term neurodevelopment outcome and immune system should be per-
formed.
In conclusion, invasive antenatal management are equally effective
but invasive interventions have a higher risk of complications.
Therefore, maternal IVIg administration is first line treatment as an-
tenatal management in FNAIT. This recommendation was integrated in
the most recent international guideline on clinical management stra-
tegies of FNAIT [63].
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4.4. Corticosteroids
In addition to maternal IVIg treatment, corticosteroids are some-
times added as antenatal treatment in some centers and mentioned in
guidelines. However, the evidence for the use of corticosteroids is very
weak, and the fetal and maternal side effects should not be under-
estimated [63]. Winkelhorst et al. [5] assessed 11 studies that compared
IVIg treatment with and without the addition of corticosteroids. Only
one study showed an increase in platelet count [69], while all other
studies failed to report beneficial effects. Given the important side ef-
fects and the lack of evidence for a beneficial effect, we think that this
treatment should not be applied as first line treatment in FNAIT.
4.5. Mode and timing of delivery
Peripartum management should be focused on reduction of the risk
of bleeding by minimizing the factors contributing to bleeding com-
plications. Strong evidence for best peripartum strategies is lacking.
There is consensus about reticence in the use scalp electrodes, scalp
blood samplings or assisted vaginal delivery. Elective cesarean delivery
is the preferred mode of delivery in some centers. This is based on the
assumption that delivery could trigger ICH in FNAIT cases, based on a
retrospective cohort study. In this study, 200 FNAIT cases were de-
scribed, all of the 17 FNAIT related ICH occurred before or within 24 h
after birth [51]. However, in this retrospective study no routine ultra-
sound prior to and after delivery was performed. Time-point of devel-
opment of ICH is therefore not certain or by definition induced by de-
livery. Van den Akker et al. [70] performed a cohort study on standard
risk FNAIT pregnancies. In this study 23 vaginal deliveries and 9 ce-
sarean sections (CS) were included, and they showed that vaginal de-
livery was not associated with an increased risk on ICH. Another ar-
gument to reconsider routine near term elective cesareans is the risk on
neonatal complications. Neonatal complications related to pulmonary
maladaptation or prematurity were observed in 37 (21.5 %) of the
neonates in the large prospective Norwegian screening study that per-
formed near team CS to prevent ICH [45]. In our opinion, given the lack
of evidence and the potential increased risks of neonatal morbidity, CS
should not routinely be performed in FNAIT pregnancies.
4.6. Future treatment options
In analogy to the prevention of RhD using immunoprophylaxis,
prevention of immunization and development of FNAIT has been shown
to be effective in a murine model [71]. However, no clinical trials have
yet confirmed this effect in humans. In this issue, Kjær M et al. [72]
discuss the challenges of developing a hyperimmune anti-HPA-1a IgG
for the prevention of HPA-1a-immunization. Another future therapeutic
option might be an FcRn receptor blocker that can inhibit the trans-
portation of alloantibodies over the placenta. Preclinical studies
showed promising results [73], and a study in red cell alloimmunized
pregnancies is currently ongoing [74].
5. Postnatal management: optimal transfusion thresholds and
platelet product
5.1. Transfusion threshold
The optimal postnatal management strategy for neonates with
FNAIT is unknown, and is currently mostly based on expert opinions
and single center observational data. Due to the rarity of disease and its
heterogeneity, randomized trials will need a high number of inclusions
and a large consortium contributing to the study. A recent systematic
review on the postnatal treatment concludes that there is no sufficient
evidence on the optimal postnatal treatment to prevent bleeding in
infants that suffer from FNAIT [6]. After birth, prophylactic platelet
transfusions are advised in case of severe thrombocytopenia in virtually
all guidelines, but transfusion thresholds vary. Prophylactic platelet
transfusions are given to prevent bleedings, but the evidence for the
preventive effect of platelet transfusions is controversial and has re-
cently been questioned [75–77]. In a recent systematic review, the
opposite was found to be more plausible, as transfusions in thrombo-
cytopenic preterm neonates were associated with increased risk of
bleeding [78]. A recently published randomized trial on prophylactic
platelet transfusions thresholds in preterm infants confirmed the results
of the systematic review [79]. This study showed that a higher platelet
transfusion threshold (50 × 109/L) was associated with a higher
mortality rate and bleeding than a more restrictive transfusion
threshold (25 × 109/L). Although this study included only preterm
neonates and excluded neonates with FNAIT, one could argue that
prophylactic transfusions in FNAIT neonates, with potentially fragile
vessel walls due to endothelial damage, could be harmful too. A ran-
domized trial in FNAIT neonates would be required to determine the
optimal transfusion threshold. Until then, we suggest to follow national
guidelines and transfer knowledge obtained from randomized trails
performed in preterm infants. Fig. 3 provides an overview of a Dutch
transfusion guideline in FNAIT. A transfusion threshold of 50 × 109/L
in neonates suffering from FNAIT with active bleeding is suggested and
a threshold of 25 × 109/L in neonates without active bleeding.
5.2. Platelet product
HPA-typed platelets, negative for the implicated HPA antigen, have
Fig. 2. Flowchart antenatal treatment.
FNAIT: Fetal and neonatal alloimmune thrombocytopenia, ICH: intracranial haemorrhage, TOP: termination of pregnancy, IVIg: Intravenous immune globulin, gr/
kg/week: grams per kilogram (bodyweight) per week.
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traditionally been regarded as the optimal platelet product in FNAIT
neonates, as these products would not be susceptible to the pathogenic
antibodies present in these children. In a recent study in a national
cohort in 102 firstly diagnosed FNAIT cases, we found a similar platelet
increment in both HPA-matched and random platelet transfusions [80].
In our opinion, random platelet transfusions could be viewed as first-
line treatment in case acute bleeding or severe thrombocytopenia. In
most countries, HPA-matched platelets are not readily available and
reducing delay by using random platelets may be preferable. No large
benefits of neonatal IVIg treatment were observed in our small cohort
[80]. Also the beneficial effect of IVIg treatment postnatal is questioned
in a recent systematic review on postnatal treatment in FNAIT [6].
Pragmatically we advise to perform a platelet transfusion without delay
using random platelets, at a platelet count< 25 × 109/L or in case of a
severe bleeding, unless a HPA-matched product is readily available.
IVIg treatment is not advised as first line postnatal treatment.
6. Long-term outcome
Literature about the long-term outcome on FNAIT without ICH is
scarce [2,20]. The first follow-up study on FNAIT cases was performed
by Ward et al. [81] and published in 2006. They concluded that de-
velopment of children treated for FNAIT was better compared to their
non-treated siblings. Their conclusions were based on non-validated
questionnaires taken by telephone, assessing the behavioral outcome of
the children and were limited by a 40 % lost-to-follow-up rate. A second
follow-up study including 39 children was published by a research
group from our center in 2004. This study showed that the outcome in
children with FNAIT and exposed to maternal IVIg treatment was si-
milar to the normal population [68]. However, this study included a
heterogenic group of children with different treatment strategies in-
cluding IUT, hampering definitive conclusions. More research is needed
to provide insight in the long/term development of children that suf-
fered from FNAIT.
7. Future perspectives
The introduction of an antenatal screening on FNAIT has been a
topic of scientific debate in the past decades and has been discussed by
the health authorities in several countries, for instance Norway,
Denmark, the United Kingdom and the Netherlands. The World Health
Organization stimulated the use of the criteria fromWilson and Jüngner
to decide whether a population screening program is of benefit to a
population and the overall health care system. These criteria can be
used to guide the debate on antenatal screening on FNAIT [82]. Two of
these criteria should be priority in research on FNAIT. First, the natural
course and incidence on FNAIT should be addressed. Second, attention
should be paid to the development of diagnostic tools to identify the
pregnancies at risk for severe neonatal outcome. As discussed earlier,
most studies that address the incidence of FNAIT are either performed
retrospectively or performed prospectively in combination with inter-
ventions. Therefore, results on the natural course of the disease could
be biased. Importantly, most studies used platelet count as a primary
outcome marker instead of clinically more relevant outcomes such as
major bleeding and/or perinatal death [4]. Conducting a study that
addresses these outcomes will be extremely challenging since the in-
cidence of these major bleeding is estimated on 1 in 10.000 pregnancies
and thousands of pregnancies would have to be screened. An important
research priority on this subject is the development of diagnostic tools
to predict clinical outcome, hence to identify the cases who need an-
tenatal therapy and interventions. Future international collaborative
research involving both clinicians and scientists might lead to this di-
agnostic assay to identify pregnancies at risk and prevent burden of
FNAIT in future.
7.1. Towards routine HPA-screening in pregnancy to prevent FNAIT – the
HIP study
In 2017, a large prospective screening study started in the
Netherlands to assess the incidence on clinical relevant FNAIT cases
[83,84]. Maternal serum samples of HPA-1a negative and HPA-1a po-
sitive controls and clinical data are collected. We expect to end our
study in spring 2020. In contrast to other screening studies, this study is
completely observational without any perinatal management applied,
which allows the assessment of the natural history of this disease. More
importantly, this study will provide a uniform serum sample collection
(alloimmunized pregnancies without clinical disease) that can be used
to develop and test diagnostic assays to identify pregnancies at risk. In
this way the HIP study will contribute important knowledge and pro-
vide arguments in the debate on antenatal screening on FNAIT.
8. Conclusion
FNAIT causes severe burden and fetal ICH in 1 in 10.000 pregnan-
cies. Antenatal, non-invasive treatment strategies are nowadays viewed
as preferred management since they bear a lower risk of intrauterine
complications. In high-risk FNAIT, antenatal IVIg treatment should be
initiated at 12–18 weeks gestational age, using a high dosage. In stan-
dard-risk FNAIT antenatal IVIg should be started between 20–28 weeks
gestational age using a lower dosage. Postnatal treatment strategies
consist of platelet transfusions in case of severe thrombocytopenia,
using either HPA-selected or unselected, depending on which one is
more readily available. The optimal threshold for prophylactic trans-
fusion is not known and varies between countries. A more restrictive
Fig. 3. Flowchart postnatal treatment.
This flowchart is based on the Dutch transfusion guideline for infants.
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transfusion strategy using a lower platelet threshold was recently
shown to be superior to a liberal strategy using a higher threshold in
preterm neonates. Whether this may also apply to term neonates with
FNAIT is not known. Further studies are needed to evaluate the natural
history and long-term neurodevelopmental outcome in FNAIT to opti-
mize risk assessment and identify pregnancies at risk for ICH.
Prevention of FNAIT is key, and can be achieved by antenatal screening.
Implementation of national screening programs will probably strongly
reduce the burden of this severe disease.
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